Perspective for Drug Discovery Targeting SARS Coronavirus Methyltransferases: Function, Structure and Inhibition

被引:1
|
作者
Li, Xin [1 ,2 ]
Song, Yongcheng [1 ,2 ]
机构
[1] Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Pharmacol, Houston, TX 77030 USA
[2] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA
关键词
SARS-COV-2 ANTIVIRAL COMPOUNDS; SMALL-MOLECULE INHIBITORS; RNA; NSP14; REPLICATION; ATTENUATION; DOMAIN; SPIKE; ACE2;
D O I
10.1021/acs.jmedchem.4c01749
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Severe acute respiratory syndrome-associated coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is highly contagious and caused a catastrophic pandemic. It has infected billions of people worldwide with >6 million deaths. With expedited development of effective vaccines and antiviral drugs, there have been significantly reduced SARS-CoV-2 infections and associated mortalities and morbidities. The virus is closely related to SARS-CoV, which emerged in 2003 and infected several thousand people with a higher mortality rate of similar to 10%. Because of continued viral evolution and drug-induced resistance, as well as the possibility of a new coronavirus in the future, studies for new therapies are needed. The viral methyltransferases play critical roles in SARS coronavirus replication and are therefore promising drug targets. This review summarizes the function, structure and inhibition of methyltransferases of SARS-CoV-2 and SARS-CoV. Challenges and perspectives of targeting the viral methyltransferases to treat viral infections are discussed.
引用
收藏
页码:18642 / 18655
页数:14
相关论文
共 50 条
  • [41] Traditional Chinese medicine is a resource for drug discovery against 2019 novel coronavirus (SARS-CoV-2)
    Ling, Chang-quan
    JOURNAL OF INTEGRATIVE MEDICINE-JIM, 2020, 18 (02): : 87 - 88
  • [42] Promising inhibitors targeting Mpro: an ideal strategy for anti-SARS-CoV-2 drug discovery
    Yi Chen
    Guan Wang
    Liang Ouyang
    Signal Transduction and Targeted Therapy, 5
  • [43] Promising inhibitors targeting Mpro: an ideal strategy for anti-SARS-CoV-2 drug discovery
    Chen, Yi
    Wang, Guan
    Ouyang, Liang
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2020, 5 (01)
  • [44] A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus?
    Oscanoa, Teodoro J.
    Romero-Ortuno, Roman
    Carvajal, Alfonso
    Savarino, Andrea
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 56 (03)
  • [45] HDAC8 as a target in drug discovery: Function, structure and design
    Zhao, Qianlong
    Liu, Hongyan
    Peng, Jie
    Niu, Haoqian
    Liu, Jingqian
    Xue, Haoyu
    Liu, Wenjia
    Liu, Xinyu
    Hao, Huabei
    Zhang, Xinbo
    Wu, Jingde
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 280
  • [46] Molecular dynamics simulations: from structure function relationships to drug discovery
    Pramod C Nair
    John O Miners
    In Silico Pharmacology, 2 (1)
  • [47] G-Protein coupled receptors: structure and function in drug discovery
    Odoemelam, Chiemela S.
    Percival, Benita
    Wallis, Helen
    Chang, Ming-Wei
    Ahmad, Zeeshan
    Scholey, Dawn
    Burton, Emily
    Williams, Ian H.
    Kamerlin, Caroline Lynn
    Wilson, Philippe B.
    RSC ADVANCES, 2020, 10 (60) : 36337 - 36348
  • [48] Evaluating the 3C-like protease activity of SARS-Coronavirus: Recommendations for standardized assays for drug discovery
    Grum-Tokars, Valerie
    Ratia, Kiira
    Begaye, Adrian
    Baker, Susan C.
    Mesecar, Andrew D.
    VIRUS RESEARCH, 2008, 133 (01) : 63 - 73
  • [49] Targeting the SARS-CoV2 nucleocapsid protein for potential therapeutics using immuno-informatics and structure-based drug discovery techniques
    Kwarteng, Alexander
    Asiedu, Ebenezer
    Sakyi, Samuel Amoah
    Asiedu, Samuel Opoku
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 132
  • [50] Anthraquinone as a privileged structure in drug discovery targeting P2Y receptors
    Baqi, Younis
    Scheiff, Anja B.
    Mueller, Christa E.
    PURINERGIC SIGNALLING, 2012, 8 (01) : 143 - 144